DARÉ IN ITALIAN, IT MEANS “TO GIVE.” IN ENGLISH, IT MEANS “TO BE BOLD.” Women At Daré Bioscience, women’s health is Our Sole Focus. Innovation in women’s health needs to be a priority. We are working hard to identify and advance new therapies that provide additional choices and improve outcomes so that we can make a difference in the lives of women everywhere. ...

Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and Chief Executive Officer John Fair - Chief Commercial Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants Catherine Novack - Jones Research Operator Welcome to the conference hosted by Daré Bioscience to review the Company’s Financial Results for the Quarter Ended June 30, 2023, and to provide a General Business Update. T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-4139823 (State or Other Jurisdictio ...

财务数据和关键指标变化 - 公司第一季度总综合亏损约为800万美元 [42] - 公司于3月31日的现金及现金等价物约为1980万美元,普通股发行在外股数约为8630万股 [43] 各条业务线数据和关键指标变化 - 公司没有提供各业务线的具体数据和指标变化 各个市场数据和关键指标变化 - 公司没有提供各市场的具体数据和指标变化 公司战略和发展方向及行业竞争 - 公司专注于女性健康领域,拥有1个获批产品和12个处于开发阶段的候选药物 [8] - 公司的产品候选药物需要满足以下三个原则:1)解决重大市场需求;2)有潜力成为首选或首创产品;3)已有临床或非临床验证数据 [8] - 公司目前的创新重点包括避孕、阴道健康、生殖健康、更年期、性健康和生育 [9] - 公司认为女性性唤起障碍(FSAD)市场可能与男性勃起障碍(ED)市场规模相当或更大 [15][16] - 公司认为Sildenafil软膏有望成为首个获批治疗FSAD的产品,开创一个全新的市场 [16] - 公司正与美国国立卫生研究院合作开展Ovaprene关键性临床试验,预计2023年中启动患者入组 [25] - 公司正在澳大利亚开展DARE-PDM1(用于治疗痛经)的临床试验,预计今年公布试验结果 [26][27] 管理层对经营环境和未来前景的评论 - 公司认为Sildenafil软膏有望成为首个获批治疗FSAD的产品,开创一个全新的市场,与男性勃起障碍(ED)市场规模相当或更大 [15][16][22][24] - 公司认为XACIATO有望在第二季度实现首次商业销售 [39] - 公司正在探索各种筹资方式,包括非稀释性补助、股权融资、许可协议、结构性融资和战略合作等,以满足运营需求、推进候选药物开发并创造股东价值 [43][44] 问答环节重要的提问和回答 问题1 **Catherine Novack 提问** - 对于Sildenafil软膏的临床试验,公司如何区分性唤起和性欲两个不同的指标,FDA对此有何要求? [47][48][49][50][51] **Sabrina Martucci Johnson 回答** - 公司在临床试验中使用了一些已验证的问卷,涵盖性唤起、润滑、高潮等多个方面,同时还设计了一些探索性指标,通过访谈女性患者了解她们关注的身体感受 [48][49][50][51] - FDA的指导原则将性唤起障碍和性欲低下视为两个不同的适应症,公司的Sildenafil软膏主要针对的是性唤起障碍这一身体症状 [49][50][51] 问题2 **Kumar Raja 提问** - 公司何时能获得Sildenafil软膏临床试验的完整数据集? [60][61][62][63] - 公司计划如何利用最新的热成像研究结果支持Sildenafil软膏的开发? [64][65][66][67] **Sabrina Martucci Johnson 回答** - 公司正在尽快分析临床试验数据,但由于数据量很大,需要谨慎周详地进行分析,以确保为FDA提供最佳的临床方案 [61][62][63] - 公司最近启动了一项补充性的热成像研究,旨在进一步了解Sildenafil软膏的作用机制和给药时间,为III期临床试验的设计提供支持 [64][65][66][67] 问题3 **Kemp Dolliver 提问** - XACIATO的商业化进展如何,Organon何时开始详细推广该产品? [76][77][78][79] - XACIATO的收益分成情况如何,公司需要支付许可方哪些费用? [83][84][85][86][89][90] **Sabrina Martucci Johnson和Lisa Walters-Hoffert回答** - Organon已经开展了一系列推广活动,包括参加行业会议、与医生和支付方互动等,预计第二季度实现首次商业销售 [77][78][79] - 公司与许可方MilanaPharm的协议中,只有在销售额超过5000万美元时需支付100万美元里程碑费,其他收益分成安排较低 [84][85][86][89][90]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-4139823 (State or Other Jurisdicti ...

Dare Bioscience, Inc. (NASDAQ:DARE) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Sabrina Johnson - President & Chief Executive Officer Lisa Walters-Hoffert - Chief Financial Officer John Fair - Chief Strategy Officer Conference Call Participants Catherine Novack - Jones Research Douglas Tsao - H.C. Wainwright Kumaraguru Raja - ROTH Capital Joanne Lee - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Welcome to the conference call hosted by Daré Bioscience to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________ FORM 10-K ___________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO_____ Commission File No. 001-36395 DARÉ BIOSCIENCE, INC. (Exa ...